Jilin Aodong Pharmaceutical Group Co Ltd (000623) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Jilin Aodong Pharmaceutical Group Co., Ltd. manufactures and sells pharmaceutical products in China.
Total Cash From Operating Activities Chart for Jilin Aodong Pharmaceutical Group Co Ltd
Jilin Aodong Pharmaceutical Group Co Ltd (000623) operating cash flow for FY2025 was CNY 272.3M, a 357.7% change from FY2024. Jilin Aodong Pharmaceutical Group Co Ltd's operating cash flow moved from CNY -30.9M in 1998 to CNY 272.3M in 2025 over 27 years. Operating cash flow compound annual growth rate: 5-year CAGR of -7.0%, 10-year CAGR of -3.5%, 20-year CAGR of 3.5%.
Total Cash From Operating Activities (CNY)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- ¥22.27B
- Implied Share Price
- ¥18.62
- Enterprise Value
- ¥21.69B
- Revenue (TTM)
- ¥2.23B
- EBITDA
- ¥38.93M
- Profit Margin
- 123.25%
- Trailing P/E
- 7.96
- Forward P/E
- 14.62
- Price/Book (MRQ)
- 0.71
- Price/Sales (TTM)
- 10.00
- EV/EBITDA
- 7.70
- EV/Revenue
- 9.74
- Dividend Yield
- 2.68%
- Book Value
- ¥26.86
- Free Cash Flow (FY2025)
- ¥143.81M
- Free Cash Flow Yield
- 0.65%
Snapshot as of 28th August 2026 — not point-in-time controlled, may lag the live market by a few days.